Company news

Savara, Inc. news in 2026

Savara, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment

October 21, 2026

Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026

October 12, 2026

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP)

August 25, 2026

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026

Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041

July 30, 2026

Savara Announces Chief Financial and Administrative Officer Transition

June 8, 2026

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

May 27, 2026

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

May 20, 2026

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

May 19, 2026

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

May 18, 2026

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

May 11, 2026

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

April 14, 2026

Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference

April 14, 2026

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency Has Accepted the MOLBREEVI Marketing Authorisation Application for Autoimmune Pulmonary Alveolar Proteinosis

April 8, 2026

Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

April 6, 2026

Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

March 29, 2026

Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

March 13, 2026

Savara Provides Regulatory Update on the MOLBREEVI Development Program in Autoimmune Pulmonary Alveolar Proteinosis

March 9, 2026

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

March 5, 2026

Savara Announces Participation in 2026 Citizens Life Sciences Conference

March 3, 2026

Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

February 20, 2026

Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*

January 26, 2026

Savara Announces New Employment Inducement Grant

January 16, 2026

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*

January 8, 2026

Decks in 2026